» Articles » PMID: 17314277

Rapid Turnover of Apolipoprotein C-III-containing Triglyceride-rich Lipoproteins Contributing to the Formation of LDL Subfractions

Overview
Journal J Lipid Res
Publisher Elsevier
Specialty Biochemistry
Date 2007 Feb 23
PMID 17314277
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

The atherogenicity theory for triglyceride-rich lipoproteins (TRLs; VLDL + intermediate density lipoprotein) generally cites the action of apolipoprotein C-III (apoC-III), a component of some TRLs, to retard their metabolism in plasma. We studied the kinetics of multiple TRL and LDL subfractions according to the content of apoC-III and apoE in 11 hypertriglyceridemic and normolipidemic persons. The liver secretes mainly two types of apoB lipoproteins: TRL with apoC-III and LDL without apoC-III. Approximately 45% of TRLs with apoC-III are secreted together with apoE. Contrary to expectation, TRLs with apoC-III but not apoE have fast catabolism, losing some or all of their apoC-III and becoming LDL. In contrast, apoE directs TRL flux toward rapid clearance, limiting LDL formation. Direct clearance of TRL with apoC-III is suppressed among particles also containing apoE. TRLs without apoC-III or apoE are a minor, slow-metabolizing precursor of LDL with little direct removal. Increased VLDL apoC-III levels are correlated with increased VLDL production rather than with slow particle turnover. Finally, hypertriglyceridemic subjects have significantly greater production of apoC-III-containing VLDL and global prolongation in residence time of all particle types. ApoE may be the key determinant of the metabolic fate of atherogenic apoC-III-containing TRLs in plasma, channeling them toward removal from the circulation and reducing the formation of LDLs, both those with apoC-III and the main type without apoC-III.

Citing Articles

Multifaceted Role of Apolipoprotein C3 in Cardiovascular Disease Risk and Metabolic Disorder in Diabetes.

Pan B, Chen C, Chen F, Shen M Int J Mol Sci. 2024; 25(23.

PMID: 39684468 PMC: 11641554. DOI: 10.3390/ijms252312759.


Role of APOC3 3238C/G, APOB 12669G/A and SCARB1 1050C/T polymorphisms, their expression in patients of HIV-associated lipodystrophy.

Singh H, Shyamveer , Jori C, Mahajan S, Aalinkeel R, Kaliyappan K Heliyon. 2024; 10(9):e30519.

PMID: 38742060 PMC: 11089352. DOI: 10.1016/j.heliyon.2024.e30519.


Exploring apolipoprotein C-III: pathophysiological and pharmacological relevance.

Packard C, Pirillo A, Tsimikas S, Ference B, Catapano A Cardiovasc Res. 2023; 119(18):2843-2857.

PMID: 38039351 PMC: 11484501. DOI: 10.1093/cvr/cvad177.


Pharmacological Inhibition of CETP (Cholesteryl Ester Transfer Protein) Increases HDL (High-Density Lipoprotein) That Contains ApoC3 and Other HDL Subspecies Associated With Higher Risk of Coronary Heart Disease.

Furtado J, Ruotolo G, Nicholls S, Dullea R, Carvajal-Gonzalez S, Sacks F Arterioscler Thromb Vasc Biol. 2021; 42(2):227-237.

PMID: 34937388 PMC: 8785774. DOI: 10.1161/ATVBAHA.121.317181.


Metabolism of Triglyceride-Rich Lipoproteins.

Boren J, Taskinen M Handb Exp Pharmacol. 2021; 270:133-156.

PMID: 34676434 DOI: 10.1007/164_2021_520.